Fortunately, after 2010, more efficacious targeted therapy was demonstrated, best exemplified by the adoption of trastuzumab for Human Epidermal Growth Factor Receptor 2 (HER-2)-positive gastric cancer. The gene discussed is ERBB2; the disease is gastric cancer.